(Q24799187)

English

Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response

scientific article

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response (English)

0 references

0 references

1 reference

3

0 references

Włodzimierz Maśliński

series ordinal

2

object named as

Wlodzimierz Maslinski

0 references

author name string

Hubert Marotte

series ordinal

1

0 references

language of work or name

English

0 references

publication date

2005

0 references

published in

Arthritis Research and Therapy

0 references

volume

7

0 references

issue

1

0 references

page(s)

R149-55

0 references

cites work

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064892

retrieved

7 April 2017

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064892

retrieved

7 April 2017

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064892

retrieved

7 April 2017

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064892

retrieved

28 September 2017

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064892

retrieved

28 September 2017

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064892

retrieved

28 November 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064892

retrieved

28 November 2018

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15642135

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15642135

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15642135

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15642135

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1186/AR1465

0 references

Dimensions Publication ID

1038705377

0 references

PMC publication ID

1064892

0 references

PubMed publication ID

15642135

0 references

ResearchGate publication ID

8089466

0 references

(Q24799187)

Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)